How IHC results go from unreliable to reproducible — and the role cell line controls play in locking in quality at every step.
IHC sounds straightforward in principle — apply an antibody, see where it stains, interpret the pattern. In practice, getting a clean, reliable result requires careful calibration. Use too much antibody, and the stain bleeds into areas where the protein isn’t actually present (false positives). Use too little, and real expression goes undetected (false negatives). The wrong incubation time, diluent, or tissue preparation can produce the same problems.
This process of finding the right conditions — antibody concentration, incubation time, blocking steps, antigen retrievalA preparatory step that “unmasks” proteins in FFPE tissue that were chemically altered during fixation, allowing the antibody to bind correctly. — is called antibody optimizationThe process of testing an antibody at multiple concentrations to find the optimal amount that produces clear, specific staining with minimal background noise., and it has to happen before any staining result can be trusted diagnostically.
The critical issue is reproducibility: a test that works perfectly in one laboratory needs to produce the same result in another, on a different day, with different staff. Without standardized controls built into every run, there’s no reliable way to confirm that a result reflects the patient’s biology rather than a technical variable in that day’s staining run.
Controls are the quality assurance layer of IHC. Every staining run includes control samples alongside the patient tissue — not to generate diagnostic information, but to verify the run itself is performing correctly before trusting any patient result.
Positive controlsA sample known to express the target protein, run alongside patient tissue to confirm the staining procedure worked correctly. are samples known to express the target protein. If a positive control doesn’t stain when it should, something went wrong with the procedure — and any patient results from that run can’t be trusted. They confirm the antibody, reagents, and protocol are all working.
Negative controlsA sample known not to express the target protein, used to detect any false-positive or non-specific background staining. are samples known not to express the target protein. If a negative control stains, it signals non-specific bindingWhen an antibody sticks to structures it wasn’t designed to target, producing misleading background staining. — a false positive problem that would also affect patient tissue on the same run.
Cell lines make particularly reliable controls because their protein expression levels are stable, well-characterized, and reproducible. Unlike human tissue samples — which vary between patients, fixation batches, and processing conditions — cell lines can be prepared consistently as FFPE cell blocksFormalin-fixed, paraffin-embedded cells prepared the same way as patient tissue, used as a standardized control material. that behave like tissue under the microscope. This makes them ideal as a fixed reference point: you always know what they should look like, so any deviation is immediately meaningful.
Finding the optimal antibody concentration is done through titrationThe process of testing an antibody at multiple concentrations to find the optimal amount that produces clear, specific staining with minimal background noise. — running the same antibody at a series of dilutions (for example, 1:50, 1:100, 1:200, 1:400) against a positive control and a negative control simultaneously, then comparing results. The goal is the concentration that produces the highest signal-to-noise ratioThe balance between true staining signal (where the protein is) and background noise (non-specific staining everywhere else) — higher is better.: strong, specific staining where the protein should be, and clean background where it shouldn’t.
Identify the biomarker of interest and choose a primary antibody validated for IHC use. Antibody selection depends on the protein being targeted, the host species the antibody was raised in, and the detection platform. Not all antibodies against the same protein perform equally — clone selection, lot consistency, and vendor validation data all affect how a result translates to patient tissue.
Source or prepare FFPE cell blocks from cell lines with known, stable expression of the target protein (positive control) and known absence of the protein (negative control). Cell lines are preferred over patient tissue as controls because their expression levels are consistent and reproducible across preparations — you always know what they should look like, so any deviation is immediately flagged.
Run the same antibody at multiple dilutions — for example 1:50, 1:100, 1:200, and 1:400 — against both the positive and negative controls simultaneously. Every concentration is stained and processed under the exact same conditions so that only the antibody concentration varies. This isolation is what makes the result interpretable.
Evaluate each concentration side by side. Too concentrated: both controls stain heavily — the positive and negative look similar, making it impossible to distinguish true expression from background. Too dilute: the positive control barely stains, meaning real expression in patient tissue would be missed. The optimal concentration is the one with the highest ratio of true signal to background noise.
Once the optimal concentration is identified — the dilution that gives the clearest distinction between positive and negative controls — it’s validated and locked in as the standard working concentration for that antibody on that platform. From this point forward, all patient staining runs for that biomarker use this concentration. Any future change requires re-validation.
Optimization doesn’t end once conditions are set. Cell line controls must be run alongside patient tissue on every staining batch, indefinitely. A control that stains correctly on Tuesday doesn’t guarantee the same on Friday — reagents degrade, instruments drift, technicians vary. Controls are the mechanism that catches these shifts before they reach a patient report.
Once optimal conditions are established, they need to be validated and locked in, so that every subsequent staining run produces equivalent results regardless of when or where it’s performed.
PCI-AI’s TriControl™, QuadControl™, and DualControl™ panels provide ready-made, characterized cell line controls covering multiple expression levels of a given biomarker — built specifically to streamline the titration and quality control process. Rather than sourcing and preparing individual control cell lines separately for each biomarker, a lab can run a single panel slide alongside patient tissue and immediately confirm whether staining intensity falls within the expected range across high, medium, and low (or absent) expression levels.
This is the real-world application of the control concepts above: each circular plug on a TriControl™ slide represents a different, pre-characterized expression tier, so a pathologist can calibrate their read of a patient slide against a built-in reference on the same physical glass. The panel replaces steps 2 through 4 of the titration workflow above with a single ready-made tool — one that has already been validated across those expression levels by PCI-AI.
Null, wild-type, and diffuse expression profiles in a single FFPE cell block. Run it alongside patient tissue to verify antibody performance and calibrate scoring across the full expression range — all without sourcing separate control tissue for each biomarker.
View all control panels →